Relmada Therapeutics SG&A Expense (Quarterly) Trends

Relmada Therapeutics Inc (RLMD)

3.35 -0.14 (-4.01%) USD | NASDAQ | May 17, 16:00

3.35 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2012. Upgrade now.

Date	Value
March 31, 2024	9.683M
December 31, 2023	12.08M
September 30, 2023	12.24M
June 30, 2023	12.29M
March 31, 2023	12.29M
December 31, 2022	11.83M
September 30, 2022	8.208M
June 30, 2022	14.60M
March 31, 2022	13.28M
December 31, 2021	8.909M
September 30, 2021	8.660M
June 30, 2021	9.130M
March 31, 2021	8.383M
December 31, 2020	6.020M
September 30, 2020	5.946M
June 30, 2020	7.433M
March 31, 2020	5.467M
September 30, 2019	1.82M
June 30, 2019	1.066M
March 31, 2019	1.426M
December 31, 2018	2.222M
September 30, 2018	0.9897M
June 30, 2018	0.9709M
March 31, 2018	0.883M

Date	Value
December 31, 2017	1.306M
September 30, 2017	0.8151M
June 30, 2017	1.598M
March 31, 2017	1.792M
December 31, 2016	1.282M
September 30, 2016	1.252M
June 30, 2016	2.489M
March 31, 2016	2.138M
December 31, 2015	3.604M
September 30, 2015	1.764M
June 30, 2015	1.538M
March 31, 2015	2.304M
December 31, 2014	2.293M
September 30, 2014	3.004M
February 28, 2014	0.0031M
November 30, 2013	0.0145M
August 31, 2013	0.0124M
May 31, 2013	0.0198M
February 28, 2013	0.0046M
November 30, 2012	0.0093M
August 31, 2012	0.0091M
May 31, 2012	0.0026M
February 29, 2012	0.0016M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

1.066M

Minimum

Jun 2019

14.60M

Maximum

Jun 2022

8.912M

Average

8.909M

Median

Dec 2021

SG&A Expense (Quarterly) Benchmarks